Exchange: NASDAQ·Updated 02:44 PM EST
HTFL logo

HTFL Heartflow, Inc.

$45.39
$1.69
(3.58%)
Today
Reported EarningsNov 12
Mkt Cap$4.14B
Vol683,648.00

About HTFL

HeartFlow, Inc. operates as a cardiovascular company which engages in diagnosing coronary artery diseases. The firm provides a patient-specific analysis of coronary blood flow utilizing coronary CT scans and proprietary computer algorithms based on computational fluid dynamics. The company was founded by Charles A. Taylor, Nathan M. Wilson, and Christopher K. Zarins in July 2007 and is headquartered in San Francisco, CA.
62

Bullish Sentiment

How do you feel about HTFL?

SilverEagle
$HTFL will be a top focus of mine for 2027. I suggest you add the Ticker to your WL. But then again, no one seems to listen. Your loss not mine.
5
StocktwitsEarnings
$HTFL Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.03 up 88.89% YoY • Reported revenue of $72.86M up 57.43% YoY • Heartflow raised FY2026 total revenue guidance to $262M to $264M from $246M to $250M and non-GAAP gross margin guidance to approximately 82.5% from approximately 82%.
1
1
JBTRADEZ254
$HTFL adding more now. People in the medical field that I know say this technology is INCREDIBLE
3
SilverEagle
$HTFL a lot of action on those 11/20 50 puts yesterday prior to ER. Guessing someone sold puts and was wanting to get long at 50. Mega bullish.
2
waveriderai
$HTFL weekly Darvas: 8-week box 45.41-54.32 (weeks of 8/24 to 10/12). Oct 20 breakout on only ~1.5x avg volume; Oct 21-29 all below average. Latest quarter (Q2): revenue +48% y/y, FY26 guide raised to $246-250M from $228-232M. Oct 30 close 59.05 (-2.4%). Confirm: holds above 54.32, then above 60.56 on rising volume. First warning: back inside the box. Full invalidation: weekly close below 45.41. Educational only, not investment advice.
1
abubnic
$HTFL AI-Driven Coronary Artery Disease management, transforming how the world's leading cause of death is detected, diagnosed, & treated. HTFL has helped clinicians manage over 650,000 Patients Worldwide The company reports Q3 Earnings on Nov 12. Q2 revenue jumped 48%, its fastest expansion rate in 8 quarters. HeartFlow's Plaque business emerged as a powerful second growth engine, contributing $7.8M in revenue in Q2. The company is not yet profitable. For Q2/26, it recorded a net loss of -$15.74 M. Piper Sandler recently raised its price target on $HTFL to $64 from $45, citing the company’s competitive position in the FFRct and plaque analysis market as competitors enter the category. The analyst projects the asymptomatic segment could generate about $22M in incremental revenue in 2030, rising to about $60M by 2032.
1
BioMedCatalyst
$HTFL holding near highs into Q3 on Nov 12. The independent FUSION trial showed FFRct cuts unnecessary invasive angiograms nearly in half. The story supports the chart.
1
BluntForceOptions
$HTFL testing upper-range breakdown The tape speaks for itself. HTFL is actively breaching its upper consolidation shelf around $45.41 (-4.25%) after slicing straight through the 50-day SMA ($51.83)... and if it closes below this zone today, it will confirm a clean structural failure. Daily momentum has already rolled over decisively, with RSI (14) dropping to 37.07 and Slow Stochs buried in bearish territory (4.28 / 13.73). Below this shelf sits a pronounced liquidity vacuum with minimal structural support until the 200-day SMA and primary target at $36.12. Holding puts from the upper-range rejection, watching for a confirmed daily close below support to open up that air pocket. Just my two cents. DYOR. NFA.
TheCatch
$HTFL Q3 release: revenue $72.9M (+57%), gross margin 83.6% vs 76.5% a year ago, FY26 revenue guide raised to $262-264M from $246-250M. Stock fell 19% the next session anyway.
shoc24
$HTFL reported earnings after the close today. Adjusted EPS beat estimates: -$0.03 vs. -$0.10 expected, according to Stock Meadow.
JBTRADEZ254
$HTFL criminal Wall Street price action. amazing earnings. Zero reason this should be down
AlertsAndNews
$HTFL TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients "Late-Breaking P4 study, simultaneously published in NEJM, shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrating pre-procedural CCTA can guide key PCI planning decisions NAVIGATE-PCI shows Heartflow PCI Navigator drove modifications to stent length and lesion prep compared to angiography alone"
Rayvio_News_Filter
$HTFL 🏥 Heartflow announced late-breaking P4 randomized clinical data showing CT-guided PCI matched IVUS one-year outcomes with shorter procedures, and NAVIGATE-PCI showed Heartflow PCI Navigator changed PCI plans in approximately 70% of patients.

Advertisement|Remove ads.